Improved Survival of IPF patients Treated With Antifibrotic Drugs Compared With Untreated Patients.
Antifibrotic drugs
GAP
IPF
Nintedanib
Pirfenidone
Survival
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
21
04
2023
accepted:
09
06
2023
medline:
24
8
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
Pirfenidone and nintedanib unequivocally inhibit FVC decline, but have been inconsistently linked to reduced mortality in phase III studies. On the contrary, real-world data show a survival benefit of antifibrotic drugs. However, it is unknown what this benefit is across different Gender, Age, and Physiology (GAP) stages. Is there a difference in transplant-free (TPF) survival of IPF patients receiving antifibrotic drugs (IPF This is a single-center observational cohort study using prospectively included patients diagnosed with IPF between 2008-2018. Primary outcomes were TPF survival difference and 1-, 2-, and 3-year cumulative mortality for IPF In total, 457 patients were included. The median transplant-free survival was 3.4 years in IPF This large real-world study showed a survival benefit in IPF
Identifiants
pubmed: 37341844
doi: 10.1007/s00408-023-00628-4
pii: 10.1007/s00408-023-00628-4
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
335-343Subventions
Organisme : ZonMw
ID : grant numbers: 842002001 and 842002003
Pays : Netherlands
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824
doi: 10.1164/rccm.2009-040GL
pubmed: 21471066
pmcid: 5450933
Ley B, Collard HR, King TE (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(4):431–440
doi: 10.1164/rccm.201006-0894CI
pubmed: 20935110
King TE, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092
doi: 10.1056/NEJMoa1402582
pubmed: 24836312
Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377(9779):1760–9. Available from: http://dx.doi.org/ https://doi.org/10.1016/S0140-6736(11)60405-4
Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 365(12):1079–1087. https://doi.org/10.1056/NEJMoa1103690
doi: 10.1056/NEJMoa1103690
pubmed: 21992121
Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082
doi: 10.1056/NEJMoa1402584
pubmed: 24836310
Taniguchi H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35(4):821–829
doi: 10.1183/09031936.00005209
pubmed: 19996196
Fang C, Huang H, Guo J et al (2020) Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. PLoS ONE 15(1):1–15
doi: 10.1371/journal.pone.0228390
Cameli P, Refini RM, Bergantini L et al (2020) Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study. Front Mol Biosci 7:1–8
doi: 10.3389/fmolb.2020.581828
Bando M, Yamauchi H, Ogura T et al (2016) Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern Med 55(5):443–448
doi: 10.2169/internalmedicine.55.5272
pubmed: 26935361
Antoniou K, Markopoulou K, Tzouvelekis A et al (2020) Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res 6(1):00172–02019. https://doi.org/10.1183/23120541.00172-2019
doi: 10.1183/23120541.00172-2019
pubmed: 32010718
pmcid: 6983495
Jo HE, Glaspole I, Grainge C et al (2017) Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the australian idiopathic pulmonary fibrosis registry. Eur Respir J. https://doi.org/10.1183/13993003.01592-2016
doi: 10.1183/13993003.01592-2016
pubmed: 28275170
Wright WA, Crowley LE, Parekh D et al (2021) Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. BMJ Open Respir Res 8(1):1–8
Behr J, Prasse A, Wirtz H et al (2020) Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: Long-term results of the INSIGHTS-IPF registry. Eur Respir J. https://doi.org/10.1183/13993003.02279-2019
doi: 10.1183/13993003.02279-2019
pubmed: 32907890
pmcid: 7487272
Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–695
doi: 10.7326/0003-4819-156-10-201205150-00004
pubmed: 22586007
Kim ES, Choi SM, Lee J et al (2015) Validation of the GAP SCORE in Korean patients with idiopathic pulmonary fibrosis. Chest 147(2):430–437
doi: 10.1378/chest.14-0453
pubmed: 25211374
Hyldgaard C, Hilberg O, Muller A et al (2014) A cohort study of interstitial lung diseases in central Denmark. Respir Med 108(5):793–979. https://doi.org/10.1016/j.rmed.2013.09.002
doi: 10.1016/j.rmed.2013.09.002
pubmed: 24636811
Krauss E, Tello S, Wilhelm J et al (2020) Assessing the effectiveness of pirfenidone in idiopathic pulmonary fibrosis: long-term, real-world data from European IPF Registry (eurIPFreg). J Clin Med 9(11):3763
doi: 10.3390/jcm9113763
pubmed: 33266405
pmcid: 7700641
Gao J, Kalafatis D, Carlson L et al (2021) Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res. https://doi.org/10.1186/s12931-021-01634-x
doi: 10.1186/s12931-021-01634-x
pubmed: 34949193
pmcid: 8697453
Guenther A, Krauss E, Tello S et al (2018) The European IPF registry (eurIPFreg): Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 19(1):1–10
doi: 10.1186/s12931-018-0845-5
Kaunisto J, Salomaa ER, Hodgson U et al (2019) Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Res. https://doi.org/10.1183/23120541.00170-2018
doi: 10.1183/23120541.00170-2018
pubmed: 31304177
pmcid: 6612605
The Idiopathic Pulmonary Fibrosis Clinical Research Network*. Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis. N Engl J Med. 2012;366(21):1968–1977.
Raghu G, Rochwerg B, Zhang Y et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192(2):e3-19
doi: 10.1164/rccm.201506-1063ST
pubmed: 26177183
Salisbury ML, Tolle LB, Xia M et al (2017) Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med 131:229–235
doi: 10.1016/j.rmed.2017.08.025
pubmed: 28947036
pmcid: 5679475
Lederer DJ, Caplan-Shaw CE, O’Shea MK et al (2006) Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 6(2):398–403
doi: 10.1111/j.1600-6143.2005.01205.x
pubmed: 16426327
Ryerson CJ, Kolb M, Richeldi L et al (2019) Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Res. https://doi.org/10.1183/23120541.00127-2018
doi: 10.1183/23120541.00127-2018
pubmed: 31044139
pmcid: 6487272
Abe M, Tsushima K, Yoshioka K et al (2020) The gender–age–physiology system as a prognostic model in patients with idiopathic pulmonary fibrosis treated with nintedanib: A longitudinal cohort study. Adv Respir Med 88(5):369–376
doi: 10.5603/ARM.a2020.0137
pubmed: 33169806
Tomassetti S, Gurioli C, Ryu JH et al (2015) The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 147(1):157–164. https://doi.org/10.1378/chest.14-0359
doi: 10.1378/chest.14-0359
pubmed: 25166895
Ozawa Y, Suda T, Naito T et al (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14(5):723–728
doi: 10.1111/j.1440-1843.2009.01547.x
pubmed: 19659650
Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143–155
doi: 10.1016/S1470-2045(13)70586-2
pubmed: 24411639
Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M et al (2017) Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study. Target Oncol 12(4):475–485
doi: 10.1007/s11523-017-0517-2
pubmed: 28702806
Miura Y, Saito T, Tanaka T et al (2018) Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig 56(1):72–79. https://doi.org/10.1016/j.resinv.2017.09.007
doi: 10.1016/j.resinv.2017.09.007
pubmed: 29325685
Krämer M, Markart P, Drakopanagiotakis F et al (2020) Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system. Cell Signal 65:109432. https://doi.org/10.1016/j.cellsig.2019.109432
doi: 10.1016/j.cellsig.2019.109432
pubmed: 31693876
Dhooria S, Agarwal R, Sehgal IS et al (2020) A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffus Lung Dis 37(2):148–157
Dobashi M, Tanaka H, Taima K et al (2021) The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study. SAGE Open Med 9:205031212110233
doi: 10.1177/20503121211023357
Fletcher SV, Jones MG, Renzoni EA et al (2018) Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Res 4(4):00049–02018
doi: 10.1183/23120541.00049-2018
pubmed: 30364342
pmcid: 6194204
Okuda R, Hagiwara E, Baba T et al (2013) Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 107(9):1431–1437. https://doi.org/10.1016/j.rmed.2013.06.011
doi: 10.1016/j.rmed.2013.06.011
pubmed: 23849626
Vancheri C, Sebastiani A, Tomassetti S et al (2019) Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respir Med 156:78–84. https://doi.org/10.1016/j.rmed.2019.08.006
doi: 10.1016/j.rmed.2019.08.006
pubmed: 31445389
Wijsenbeek MS, Grutters JC, Wuyts WA (2015) Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Ther 32(7):691–704
doi: 10.1007/s12325-015-0225-1
pubmed: 26173796
pmcid: 4522034
Cottin V, Koschel D, Günther A et al (2018) Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. https://doi.org/10.1183/23120541.00084-2018
doi: 10.1183/23120541.00084-2018
pubmed: 30510957
pmcid: 6258090
Antoniou K, Markopoulou K, Tzouvelekis A et al (2020) Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. https://doi.org/10.1183/23120541.00172-2019
doi: 10.1183/23120541.00172-2019
pubmed: 33263028
pmcid: 7682660